This episode explores Persica Pharmaceuticals’ groundbreaking approach to chronic lower back pain (CLBP), focusing on treating the root cause — a low-grade bacterial infection in the spine — rather than merely alleviating symptoms. CEO Steve Ruston discusses the company’s formulation, clinical progress, and future plans.

Key Points:

Persica Pharmaceuticals pioneers an injectable, antibiotic-based therapy to treat the root cause of chronic lower back pain. Their approach may reduce opioid dependence and prevent costly spinal surgeries for millions worldwide.

• Root-Cause Focused Therapy: Persica's treatment targets a bacterial infection in spinal discs — a root cause of chronic lower back pain in about 25% of patients — distinguishing it from standard pain management methods like opioids or physiotherapy.
• Novel Injectable Formulation: The drug uses a well-known antibiotic suspended in a thermosensitive gel that solidifies in the body, delivering a concentrated dose directly to the infection site. Just two injections are required in the first week of treatment.
• Promising Clinical Results: The Phase 1b trial showed meaningful reductions in both pain and disability, with lasting effects observed up to 12 months. Patients reported improved quality of life and restored function.
• Opioid-Free Alternative with Long-Term Benefit: Unlike opioids, which mask pain without curing it, Persica’s approach aims to eliminate the infection and reduce long-term reliance on analgesics — potentially transforming pain care pathways.
• Regulatory and Market Roadmap: Persica is now engaging with regulators for Phase 3 trials in Europe and the U.S. The company is also seeking funding and partnerships to scale manufacturing and expand access.